Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen
of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small
lymphocytic leukemia (CLL/SLL).